ReviewBiomedicines2023
Preeclampsia and the Antiphospholipid Syndrome.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Screen-Detected Coeliac Disease in a Nationally Representative Cohort: Health Indicators, Long-Term Outcomes and Mortality.Alimentary pharmacology & therapeutics · 2026Article
- The pathophysiology of pre-eclampsia.Nature reviews. Nephrology · 2026Review
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- Elevated pre-eclampsia risk in lupus nephritis and antiphospholipid syndrome: a nationwide Spanish registry analysis.Rheumatology (Oxford, England) · 2026Article
- The role of neutrophil extracellular traps in antiphospholipid syndrome.Frontiers in immunology · 2026Review
- Understanding Preeclampsia: Cardiovascular Pathophysiology, Histopathological Insights and Molecular Biomarkers.Medical sciences (Basel, Switzerland) · 2025Review
- Reversing Preeclampsia Pathology: AXL Inhibition Restores Mitochondrial Function and ECM Balance.Cells · 2025Article
- Prevention of Pre-Eclampsia: Modern Strategies and the Role of Early Screening.Journal of clinical medicine · 2025Review
- Mitochondrial Oxidative Phosphorylation Alterations in Placental Tissues from Early- and Late-Onset Preeclampsia.International journal of molecular sciences · 2025Article
- Maternal Immune Activation: Implications for Congenital Heart Defects.Clinical reviews in allergy & immunology · 2025Review
- Antiphospholipid syndrome in pregnancy: a comprehensive literature review.BMC pregnancy and childbirth · 2025Review
- Multiomics analysis of neutrophils in SLE: insights from adult and paediatric disease.Clinical and experimental immunology · 2025Article
- Impaired implantation as a major upstream pathway of preeclampsia: a narrative synthesis of mechanistic, epidemiological and biomarker evidence.Frontiers in reproductive health · 2025Review
- Machine learning-based prediction of adverse pregnancy outcomes in antiphospholipid syndrome using pregnancy antibody levels.Frontiers in physiology · 2025Article
- Autoantibody production in pregnancy: relationship with mRNA BNT162b2 immunization, active COVID-19, and pre-eclampsia.Frontiers in immunology · 2025Article
- Impact of antiphospholipid syndrome on placenta and uterine NK cell function: insights from a mouse model.Scientific reports · 2024Article
- Understanding the Pathophysiology of Preeclampsia: Exploring the Role of Antiphospholipid Antibodies and Future Directions.Journal of clinical medicine · 2024Review
- Predicting Thrombophilia in Preeclampsia: Is Universal Testing Necessary?Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
- First-trimester Doppler Ultrasound for Predicting Successful Management of Pregnancy with Recurrent Pregnancy Losses Due to Antiphospholipid Syndrome and Thrombophilia: A Cohort Study.Journal of human reproductive sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is characterized by venous or arterial thrombosis and/or adverse pregnancy outcome in the presence of persistent laboratory evidence of antiphospholipid antibodies (aPLs). Preeclampsia complicates about 10-17% of pregnancies with APS. However, only early onset preeclampsia (<34 weeks of gestation) belongs to the clinical criteria of APS. The similarities in the pathophysiology of early onset preeclampsia and APS emphasize an association of these two syndromes. Overall, both are the result of a defective trophoblast invasion and decidual transformation at early gestation. Women with APS are at increased risk for prematurity; the reasons are mostly iatrogenic due to placental dysfunction, such as preeclampsia or FGR. Interestingly, women with APS have also an increased risk for preterm delivery, even in the absence of FGR and preeclampsia, and therefore it is not indicated but spontaneous. The basic treatment of APS in pregnancy is low-dose aspirin and low-molecular-weight heparin. Nevertheless, up to 20-30% of women develop complications at early and late gestation, despite basic treatment. Several additional treatment options have been proposed, with hydroxychloroquine (HCQ) being one of the most efficient. Additionally, nutritional interventions, such as intake of vitamin D, have shown promising beneficial effects. Curcumin, due to its antioxidant and anti-inflammatory properties, might be considered as an additional intervention as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.